Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 247

1.

Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A.

Chowdary P, Carcao M, Holme PA, Jiménez-Yuste V, Lentz SR, Møss J, Poulsen LH, Shen C, Tosetto A, Wheeler A, Santagostino E.

Res Pract Thromb Haemost. 2019 Jun 11;3(3):542-554. doi: 10.1002/rth2.12220. eCollection 2019 Jul.

2.

Switching patients in the age of long-acting recombinant products?

Escobar M, Santagostino E, Mancuso ME, Coppens M, Balasa V, Taylor JA, Iorio A, Negrier C.

Expert Rev Hematol. 2019;12(sup1):1-13. doi: 10.1080/17474086.2018.1564032.

PMID:
31282771
3.

Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A.

van den Berg HM, Fischer K, Carcao M, Chambost H, Kenet G, Kurnik K, Königs C, Male C, Santagostino E, Ljung R; PedNet Study Group.

Blood. 2019 Jul 18;134(3):317-320. doi: 10.1182/blood.2019000658. Epub 2019 Jun 11. No abstract available.

PMID:
31186271
4.

Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP.

Davis J, Yan S, Matsushita T, Alberio L, Bassett P, Santagostino E.

J Med Econ. 2019 Jun 5:1-8. doi: 10.1080/13696998.2019.1620246. [Epub ahead of print]

PMID:
31094591
5.

Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies.

Volkers P, Hanschmann KM, Calvez T, Chambost H, Collins PW, Demiguel V, Hart DP, Hay CRM, Goudemand J, Ljung R, Palmer BP, Santagostino E, van Hardeveld EM, van den Berg M, Keller-Stanislawski B.

Haemophilia. 2019 May;25(3):398-407. doi: 10.1111/hae.13747. Epub 2019 May 7.

PMID:
31066174
6.

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab.

Carcao M, Escuriola-Ettingshausen C, Santagostino E, Oldenburg J, Liesner R, Nolan B, Bátorová A, Haya S, Young G; Future of Immunotolerance Treatment Group.

Haemophilia. 2019 Jul;25(4):676-684. doi: 10.1111/hae.13762. Epub 2019 Apr 29.

PMID:
31033112
7.

Consensus statements on vaccination in patients with haemophilia-Results from the Italian haemophilia and vaccinations (HEVA) project.

Santagostino E, Riva A, Cesaro S, Esposito S, Matino D, Mazzucchelli RI, Molinari AC, Mura R, Notarangelo LD, Tagliaferri A, Di Minno G, Clerici M; the HEVA Study Group.

Haemophilia. 2019 Jul;25(4):656-667. doi: 10.1111/hae.13756. Epub 2019 Apr 16.

PMID:
30990961
8.

Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement.

Santagostino E, Mancuso ME, Novembrino C, Solimeno LP, Tripodi A, Peyvandi F.

Haematologica. 2019 Aug;104(8):e380-e382. doi: 10.3324/haematol.2018.215129. Epub 2019 Mar 28. No abstract available.

9.

Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis.

Samuelson Bannow B, Recht M, Négrier C, Hermans C, Berntorp E, Eichler H, Mancuso ME, Klamroth R, O'Hara J, Santagostino E, Matsushita T, Kessler C.

Blood Rev. 2019 May;35:43-50. doi: 10.1016/j.blre.2019.03.002. Epub 2019 Mar 3. Review.

10.

New data from the Italian National Register of Congenital Coagulopathies, 2016 Annual Survey.

Abbonizio F, Hassan HJ, Riccioni R, Santagostino E, Arcieri R, Giampaolo A; Italian Association of Haemophilia Centres (see Appendix).

Blood Transfus. 2019 Feb 13. doi: 10.2450/2019.0211-18. [Epub ahead of print]

11.

Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).

Curry N, Albayrak C, Escobar M, Andre Holme P, Kearney S, Klamroth R, Misgav M, Négrier C, Wheeler A, Santagostino E, Shima M, Landorph A, Tønder SM, Lentz SR.

Haemophilia. 2019 May;25(3):373-381. doi: 10.1111/hae.13712. Epub 2019 Feb 28.

PMID:
30817066
12.

Rapid and sustained immune tolerance to inhibitors induced by a plasma-derived, VWF-containing FVIII concentrate.

Santagostino E, Rangarajan S, Oldenburg J, Peiró-Jordan R, Jiménez-Yuste V.

Haemophilia. 2019 Mar;25(2):e110-e113. doi: 10.1111/hae.13676. Epub 2019 Feb 20. No abstract available.

PMID:
30786119
13.

Inhibitors: A Need for Eradication?

Santagostino E, Young G, Escuriola Ettingshausen C, Jimenez-Yuste V, Carcao M.

Acta Haematol. 2019;141(3):151-155. doi: 10.1159/000495454. Epub 2019 Feb 15. Review.

14.

Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A.

Di Minno G, Santagostino E, Morfini M, Ettorre C, Cultrera D, Baldacci E, Russo E, Gallucci C.

Patient Prefer Adherence. 2019 Jan 31;13:233-240. doi: 10.2147/PPA.S175254. eCollection 2019.

15.

Position paper on laboratory testing for patients with haemophilia. A consensus document from SISET, AICE, SIBioC and SIPMeL.

Tripodi A, Santoro RC, Testa S, Molinari AC, Bernardini S, Golato M, Lippi G, Ageno W, Santagostino E.

Blood Transfus. 2019 May;17(3):229-236. doi: 10.2450/2019.0241-18. Epub 2019 Feb 4. No abstract available.

16.

Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting.

Kruse-Jarres R, Oldenburg J, Santagostino E, Shima M, Kempton CL, Kessler CM, Lehle M, Chebon S, Selak Bienz N, Asikanius E, Mahlangu J.

Haemophilia. 2019 Mar;25(2):213-220. doi: 10.1111/hae.13655. Epub 2019 Feb 6.

PMID:
30724422
17.

Thrombin generation assay for testing hemostatic effect of factor VIII concentrates in patients with hemophilia A and inhibitors: In vitro results from the PredicTGA study.

Tripodi A, Chantarangkul V, Clerici M, Bader R, Anzoletti MB, Peyvandi F, Santagostino EM; PredicTGA Collaborators.

Thromb Res. 2019 Feb;174:84-87. doi: 10.1016/j.thromres.2018.12.007. Epub 2018 Dec 6. No abstract available.

PMID:
30579150
18.

The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.

Oldenburg J, Mahlangu JN, Bujan W, Trask P, Callaghan MU, Young G, Asikanius E, Peyvandi F, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Xu J, Windyga J, Shima M, von Mackensen S.

Haemophilia. 2019 Jan;25(1):33-44. doi: 10.1111/hae.13618. Epub 2018 Nov 14.

19.

Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients.

Ljung R, Auerswald G, Benson G, Dolan G, Duffy A, Hermans C, Jiménez-Yuste V, Lambert T, Morfini M, Zupančić-Šalek S, Santagostino E.

Eur J Haematol. 2019 Feb;102(2):111-122. doi: 10.1111/ejh.13193. Epub 2018 Dec 6. Review.

PMID:
30411401
20.

Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.

Lentz SR, Janic D, Kavakli K, Miljic P, Oldenburg J, C Ozelo M, Santagostino E, Suzuki T, Zupancic Šalek S, Korsholm L, Matytsina I, Tiede A.

Haemophilia. 2018 Nov;24(6):e391-e394. doi: 10.1111/hae.13617. Epub 2018 Nov 6.

PMID:
30402994
21.

Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study.

Mahlangu J, Oldenburg J, Callaghan MU, Shima M, Santagostino E, Moore M, Recht M, Garcia C, Yang R, Lehle M, Macharia H, Asikanius E, Levy GG, Kruse-Jarres R.

Haemophilia. 2018 Nov;24(6):921-929. doi: 10.1111/hae.13612. Epub 2018 Oct 8.

PMID:
30295389
22.

The importance of inhibitor eradication in clinically complicated hemophilia A patients.

Oldenburg J, Young G, Santagostino E, Escuriola Ettingshausen C.

Expert Rev Hematol. 2018 Nov;11(11):857-862. doi: 10.1080/17474086.2018.1521718. Epub 2018 Oct 4. Review.

PMID:
30286680
23.

Usefulness of bone microarchitectural and geometric DXA-derived parameters in haemophilic patients.

Ulivieri FM, Rebagliati GAA, Piodi LP, Solimeno LP, Pasta G, Boccalandro E, Fasulo MR, Mancuso ME, Santagostino E.

Haemophilia. 2018 Nov;24(6):980-987. doi: 10.1111/hae.13611. Epub 2018 Oct 1.

PMID:
30273987
24.

GlycoPEGylated recombinant factor IX for hemophilia B in context.

Santagostino E, Mancuso ME.

Drug Des Devel Ther. 2018 Sep 11;12:2933-2943. doi: 10.2147/DDDT.S121743. eCollection 2018. Review.

25.

Practical aspects of extended half-life products for the treatment of haemophilia.

Lambert T, Benson G, Dolan G, Hermans C, Jiménez-Yuste V, Ljung R, Morfini M, Zupančić-Šalek S, Santagostino E.

Ther Adv Hematol. 2018 Sep 6;9(9):295-308. doi: 10.1177/2040620718796429. eCollection 2018 Sep. Review.

26.

Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age-matched controls.

Mannucci PM, Nobili A, Marchesini E, Oliovecchio E, Cortesi L, Coppola A, Santagostino E, Radossi P, Castaman G, Valdrè L, Santoro C, Tagliaferri A, Ettorre C, Zanon E, Barillari G, Cantori I, Caimi TM, Sottilotta G, Peyvandi F, Iorio A.

Haemophilia. 2018 Sep;24(5):726-732. doi: 10.1111/hae.13595. Epub 2018 Aug 16.

PMID:
30112863
27.

Prophylaxis re-visited: The potential impact of novel factor and non-factor therapies on prophylaxis.

Carcao M, Lambert T, Leissinger C, Escuriola-Ettingshausen C, Santagostino E, Aledort L; International Prophylaxis Study Group (IPSG).

Haemophilia. 2018 Nov;24(6):845-848. doi: 10.1111/hae.13558. Epub 2018 Jul 10. No abstract available.

PMID:
29989273
28.

Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.

Hermans C, Mahlangu J, Booth J, Schütz H, Santagostino E, Young G, Lee HY, Steinitz-Trost KN, Blanchette V, Berntorp E.

Haemophilia. 2018 May;24(3):376-384. doi: 10.1111/hae.13483. Epub 2018 May 6.

PMID:
29732708
29.

Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors: A Survey from the Italian Association of Hemophilia Centers (AICE).

Coppola A, Franchini M, Castaman G, Santagostino E, Santoro C, Santoro RC, Morfini M, Di Minno G, Rocino A; AICE ad hoc Working Group.

Semin Thromb Hemost. 2018 Sep;44(6):551-560. doi: 10.1055/s-0038-1648230. Epub 2018 May 3. Review.

PMID:
29723892
30.

Defining extended half-life rFVIII-A critical review of the evidence.

Mahlangu J, Young G, Hermans C, Blanchette V, Berntorp E, Santagostino E.

Haemophilia. 2018 May;24(3):348-358. doi: 10.1111/hae.13438. Epub 2018 Apr 6. Review.

PMID:
29633467
31.

Desmopressin in moderate hemophilia A patients: a treatment worth considering.

Loomans JI, Kruip MJHA, Carcao M, Jackson S, van Velzen AS, Peters M, Santagostino E, Platokouki H, Beckers E, Voorberg J, van der Bom JG, Fijnvandraat K; RISE consortium.

Haematologica. 2018 Mar;103(3):550-557. doi: 10.3324/haematol.2017.180059. Epub 2018 Jan 5.

32.

Comorbidities in persons with haemophilia aged 60 years or more compared with age-matched people from the general population.

Marchesini E, Oliovecchio E, Coppola A, Santagostino E, Radossi P, Castaman G, Valdrè L, Santoro C, Tagliaferri A, Ettorre C, Zanon E, Barillari G, Cantori I, Caimi TM, Sottilotta G, Iorio A, Mannucci PM.

Haemophilia. 2018 Jan;24(1):e6-e10. doi: 10.1111/hae.13379. Epub 2017 Dec 22. No abstract available.

PMID:
29271531
33.

A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies.

Santagostino E, Young G, Carcao M, Mannucci PM, Halimeh S, Austin S.

Expert Rev Hematol. 2018 Feb;11(2):87-97. doi: 10.1080/17474086.2018.1419862. Epub 2018 Jan 4. Review.

PMID:
29258406
34.

Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors.

Mancuso ME, Fischer K, Santagostino E, Oldenburg J, Platokouki H, Königs C, Escuriola-Ettingshausen C, Rivard GE, Cid AR, Carcao M, Ljung R, Petrini P, Altisent C, Kenet G, Liesner R, Kurnik K, Auerswald G, Chambost H, Mäkipernaa A, Molinari AC, Williams M, van den Berg HM; European Pediatric Network for Haemophilia Management (PedNet) the REMAIN (REal life MAnagement of children with INhibitors) Study Group.

Thromb Haemost. 2017 Dec;117(12):2274-2282. doi: 10.1160/TH17-01-0059. Epub 2017 Dec 6.

PMID:
29212115
35.

XVI Convegno Triennale sui Problemi Clinici e Sociali dell'Emofilia e delle Malattie Emorragiche Congenite, Napoli, 9-12 Novembre 2017.

Di Minno G, Santagostino E, Morfini M, Hassan HJ, Molinari AC, Santoro RC, Tagliaferri A, Coppola A.

Blood Transfus. 2017 Nov 7;15(Suppl 4):s519-s562. doi: 10.2450/2017.s4. [Epub ahead of print] No abstract available.

36.

Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study.

Khair K, Mazzucconi MG, Parra R, Santagostino E, Tsakiris DA, Hermans C, Oldenburg J, Spotts G, Steinitz-Trost K, Gringeri A.

Haemophilia. 2018 Jan;24(1):85-96. doi: 10.1111/hae.13361. Epub 2017 Oct 17.

PMID:
29044825
37.

Ageing successfully with haemophilia: A multidisciplinary programme.

Boccalandro E, Mancuso ME, Riva S, Pisaniello DM, Ronchetti F, Santagostino E, Peyvandi F, Solimeno LP, Mannucci PM, Pasta G.

Haemophilia. 2018 Jan;24(1):57-62. doi: 10.1111/hae.13308. Epub 2017 Aug 6.

PMID:
28780767
38.

Emicizumab Prophylaxis in Hemophilia A with Inhibitors.

Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M.

N Engl J Med. 2017 Aug 31;377(9):809-818. doi: 10.1056/NEJMoa1703068. Epub 2017 Jul 10.

39.

Involvement of the IgE-basophil system and mild complement activation in haemophilia B with anti-factor IX neutralizing antibodies and anaphylaxis.

Cugno M, Mancuso ME, Tedeschi A, Santagostino E, Lorini M, Carbonelli V, Peyvandi F, Mannucci PM.

Haemophilia. 2017 Jul;23(4):e348-e353. doi: 10.1111/hae.13282. Epub 2017 Jun 8.

PMID:
28594432
40.

Polypharmacy in older adults with severe haemophilia.

Riva S, Mancuso ME, Cortesi L, Nobili A, Santagostino E, Peyvandi F, Mannucci PM.

Haemophilia. 2018 Jan;24(1):e1-e3. doi: 10.1111/hae.13262. Epub 2017 May 24. No abstract available.

PMID:
28544483
41.

First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A.

Hampton K, Chowdary P, Dunkley S, Ehrenforth S, Jacobsen L, Neff A, Santagostino E, Sathar J, Takedani H, Takemoto CM, Négrier C.

Haemophilia. 2017 Sep;23(5):689-696. doi: 10.1111/hae.13246. Epub 2017 May 4.

PMID:
28470862
42.

Platelets: much more than bricks in a breached wall.

Mancuso ME, Santagostino E.

Br J Haematol. 2017 Jul;178(2):209-219. doi: 10.1111/bjh.14653. Epub 2017 Apr 17. Review.

PMID:
28419428
43.

Insight into health-related quality of life of young children with haemophilia B treated with long-acting nonacog beta pegol recombinant factor IX.

Carcao M, Kearney S, Santagostino E, Oyesiku JOO, Young NL, Meunier J, Hoxer CS, Zhang C, Blanchette VS.

Haemophilia. 2017 May;23(3):e222-e224. doi: 10.1111/hae.13195. Epub 2017 Mar 30. No abstract available.

PMID:
28371032
44.

Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates.

Mancuso ME, Santagostino E.

J Clin Med. 2017 Mar 28;6(4). pii: E39. doi: 10.3390/jcm6040039. Review.

45.

The increased demand for plasma-derived factor VIII in Italy between 2011 and 2014 is attributable to treatment of adult patients rather than paediatric or previously unexposed patients with severe haemophilia A.

Coppola A, Santagostino E, Hassan HJ, Molinari AC, Santoro RC, Tagliaferri A, Morfini M, Di Minno G.

Blood Transfus. 2017 May;15(3):281-282. doi: 10.2450/2017.0285-16. Epub 2017 Mar 2. No abstract available.

46.

Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.

Tiede A, Abdul-Karim F, Carcao M, Persson P, Clausen WHO, Kearney S, Matsushita T, Negrier C, Oldenburg J, Santagostino E, Young G.

Haemophilia. 2017 Jul;23(4):547-555. doi: 10.1111/hae.13191. Epub 2017 Feb 24.

PMID:
28233381
47.

New findings on inhibitor development: from registries to clinical studies.

Peyvandi F, Ettingshausen CE, Goudemand J, Jiménez-Yuste V, Santagostino E, Makris M.

Haemophilia. 2017 Jan;23 Suppl 1:4-13. doi: 10.1111/hae.13137. Review.

PMID:
27990784
48.

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.

Giangrande P, Andreeva T, Chowdary P, Ehrenforth S, Hanabusa H, Leebeek FW, Lentz SR, Nemes L, Poulsen LH, Santagostino E, You CW, Clausen WH, Jönsson PG, Oldenburg J; Pathfinder™2 Investigators.

Thromb Haemost. 2017 Jan 26;117(2):252-261. doi: 10.1160/TH16-06-0444. Epub 2016 Dec 1. Erratum in: Thromb Haemost. 2017 Jun;117(6):1163.

PMID:
27904904
49.

Summary report of the First International Conference on inhibitors in haemophilia A.

Lacroix-Desmazes S, Scott DW, Goudemand J, Van Den Berg M, Makris M, Van Velzen AS, Santagostino E, Lillicrap D, Rosendaal FR, Hilger A, Sauna ZE, Oldenburg J, Mantovani L, Mancuso ME, Kessler C, Hay CRM, Knoebl P, Di Minno G, Hoots K, Bok A, Brooker M, Buoso E, Mannucci PM, Peyvandi F.

Blood Transfus. 2017 Oct;15(6):568-576. doi: 10.2450/2016.0252-16. Epub 2016 Nov 25. No abstract available.

50.

European retrospective study of real-life haemophilia treatment.

Berntorp E, Dolan G, Hay C, Linari S, Santagostino E, Tosetto A, Castaman G, Álvarez-Román MT, Parra Lopez R, Oldenburg J, Albert T, Scholz U, Holmström M, Schved JF, Trossaërt M, Hermans C, Boban A, Ludlam C, Lethagen S.

Haemophilia. 2017 Jan;23(1):105-114. doi: 10.1111/hae.13111. Epub 2016 Oct 20.

PMID:
27761962

Supplemental Content

Loading ...
Support Center